60 Degrees Pharmaceuticals (SXTP) Competitors $0.90 +0.03 (+3.45%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SXTP vs. OBSV, ATHE, GLTO, BIOR, SYRS, ABVC, CANF, EDSA, EYEN, and GTBPShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include ObsEva (OBSV), Alterity Therapeutics (ATHE), Galecto (GLTO), Biora Therapeutics (BIOR), Syros Pharmaceuticals (SYRS), ABVC BioPharma (ABVC), Can-Fite BioPharma (CANF), Edesa Biotech (EDSA), Eyenovia (EYEN), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry. 60 Degrees Pharmaceuticals vs. ObsEva Alterity Therapeutics Galecto Biora Therapeutics Syros Pharmaceuticals ABVC BioPharma Can-Fite BioPharma Edesa Biotech Eyenovia GT Biopharma ObsEva (NASDAQ:OBSV) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do insiders & institutionals believe in OBSV or SXTP? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, OBSV or SXTP? 60 Degrees Pharmaceuticals has lower revenue, but higher earnings than ObsEva. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEva$20.11M0.00-$58.38M-$0.92N/A60 Degrees Pharmaceuticals$250K8.28-$3.77M-$10.08-0.09 Does the MarketBeat Community believe in OBSV or SXTP? ObsEva received 318 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 51.37% of users gave ObsEva an outperform vote while only 14.29% of users gave 60 Degrees Pharmaceuticals an outperform vote. CompanyUnderperformOutperformObsEvaOutperform Votes31951.37% Underperform Votes30248.63% 60 Degrees PharmaceuticalsOutperform Votes114.29%Underperform Votes685.71% Does the media refer more to OBSV or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.17 indicating that ObsEva is being referred to more favorably in the media. Company Overall Sentiment ObsEva Neutral 60 Degrees Pharmaceuticals Neutral Which has more risk and volatility, OBSV or SXTP? ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 4.78, meaning that its stock price is 378% more volatile than the S&P 500. Is OBSV or SXTP more profitable? 60 Degrees Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% 60 Degrees Pharmaceuticals N/A N/A -113.43% Do analysts recommend OBSV or SXTP? Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than 60 Degrees Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.0060 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryObsEva beats 60 Degrees Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.07M$6.56B$5.22B$8.83BDividend YieldN/A8.13%5.53%4.07%P/E Ratio-0.0910.1392.5417.54Price / Sales8.28359.911,233.8694.97Price / CashN/A53.8341.4336.95Price / Book-0.5710.597.236.54Net Income-$3.77M$153.02M$119.89M$226.07M7 Day Performance0.33%3.96%2.14%3.77%1 Month Performance4.90%-6.72%-2.23%4.46%1 Year Performance59.01%30.92%32.63%27.57% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals0.7498 of 5 stars$0.90+3.4%N/A+59.0%$2.07M$250,000.00-0.093News CoverageGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastGap DownATHEAlterity Therapeutics2.77 of 5 stars$1.07+1.9%$4.00+273.8%-35.5%$7.81MN/A0.0010Gap UpGLTOGalecto3.1653 of 5 stars$5.85+0.7%$10.00+71.1%-61.9%$7.72MN/A-0.3140BIORBiora Therapeutics2.5193 of 5 stars$1.63+0.6%$23.00+1,311.0%-87.8%$7.37MN/A-0.12120SYRSSyros Pharmaceuticals4.096 of 5 stars$0.27-6.9%$3.33+1,134.6%-89.1%$7.24M$9.94M-0.09120Analyst ForecastHigh Trading VolumeABVCABVC BioPharmaN/A$0.55-3.5%N/A-70.7%$7.14M$150,000.00-0.6630Gap UpCANFCan-Fite BioPharma1.7353 of 5 stars$1.97-2.0%$18.00+813.7%-7.0%$6.97M$740,000.00-1.138Analyst DowngradeNews CoverageEDSAEdesa Biotech3.1683 of 5 stars$2.11-4.1%$21.00+895.3%-31.4%$6.86MN/A0.0020Gap DownEYENEyenovia2.8151 of 5 stars$0.11+10.5%$2.00+1,802.9%-92.0%$6.73MN/A-0.1440Analyst RevisionNews CoverageGap UpHigh Trading VolumeGTBPGT Biopharma0.478 of 5 stars$3.01-5.6%N/A-56.0%$6.71MN/A0.008News Coverage Related Companies and Tools Related Companies OBSV Competitors ATHE Competitors GLTO Competitors BIOR Competitors SYRS Competitors ABVC Competitors CANF Competitors EDSA Competitors EYEN Competitors GTBP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SXTP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredOne coin could soar when Trump’s elected …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts